PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Recipharm completes US biologics acquisitions

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announces the closing of its acquisitions of advanced therapy CDMO Arra...
Continue Reading →
News

NICE overturns previous decision, recommends Merck and Pfizer’s Bavencio

The National Institute for Health and Care Excellence (NICE) has overturned a previous decision against the routine NHS use of Merck KGaA and Pfizer’s Bavncio (avelu...
Continue Reading →
News

Connectivity, Sustainability and User Experience to transform packaging and drug delivery in next year: Pharmapack Europe 2022

Pharmapack trends are a key barometer of global device and packing opportunities in 2022 Paris, 12th April 2022: Pharmapack Europe 2022 will open i...
Continue Reading →
News

Aenova invests in new building for the production of highly potent drugs

Aenova has laid the foundation stone for the new building of highly potent active ingredients at its Regensburg site. Highly potent drugs, especially against can...
Continue Reading →
News

Mission Therapeutics launches clinical trial for kidney disease therapy

MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial Mission Therapeutics has been granted approval to take its ...
Continue Reading →
News

Positive results for Cerevance’s Parkinson’s drug

In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s symptoms recur despite medication Cerevance has announced posit...
Continue Reading →
News

Parsortix system identifies key drug targets in cancer metastasis

The study demonstrates the ability of the Parsortix system to isolate circulating tumour cells, targeting the metastatic spread of cancer. Liquid biopsy company A...
Continue Reading →
News

Novartis unveils major re-org

Novartis has announced a new organizational structure and operating model, with an eye on innovation and growth — as well as targeted savings of at least $...
Continue Reading →
News

FDA slaps partial hold on Curis leukemia study

Curis’ phase 1/2a leukaemia study is the latest to join the club of FDA clinical holds, following the death of a trial participant. The Massachusetts-based biotec...
Continue Reading →
News

CPHI North America opens as 65% of US companies forecast growth in excess of 20% in 2022

CPHI is the leading global community for pharmaceutical professionals and America's only end-to-end pharma event Kicking off the season for pharmaceutical pro...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026